title: Intravitreal triamcinolone in diabetic retinopathy.
abstract: Diabetic macular edema is an important cause of visual loss in the developed world and may frequently lead to irreversible changes in visual acuity. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema. However, some cases of diabetic macular edema are refractory to laser therapy and do not have a good prognosis with such treatment. Triamcinolone acetonide is glucocoticosteroid with antiangiogenic and antiedematous properties. Recently, some promising results, respect to the increases of visual acuity and decreases in foveal thickness, have been shown in different studies for the treatment of refractory diabetic macular edema with intravitreal triamcinolone acetonide.
authors.affiliation: Instituto Tecnológico de Oftalmología (ITO), Hospital Nuestra Señora de la Esperanza, Santiago de Compostela, Spain. mabraldes@itogalicia.es
authors.forename: Maximino J
authors.initials: MJ
authors.lastname: Abraldes
authors.forename: Maribel
authors.initials: M
authors.lastname: Fernández
authors.forename: Francisco
authors.initials: F
authors.lastname: Gómez-Ulla
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000601:surgery; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008958:Models, Molecular; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000737:chemistry / Q000627:therapeutic use*; D014821:Vitrectomy; D014822:Vitreous Body / Q000187:drug effects / Q000503:physiopathology*
chemical_list: D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide